Articles Published in 1998

This is a sequential list of news article titles from 1998 monthly issues of the Antiviral Agents Bulletin.

1. D4T Now Prescribed More Than AZT

2. Lamivudine Effective for Hepatitis B in Japanese Phase III Trial

3. FTC Shows Indications of Efficacy for HIV-Infection

4. Efficacy with Antisense HIV Gene Therapy in Primates

5. HIV Fusion Inhibitor, T-20, Enters Phase II Trials

6. Plasma Inactivation Systems in Phase II Trials

7. Maxamine/Interferon Entering Phase II Trials for Chronic Hepatitis C

8. Human Hepatitis B and CMV Antibodies Returned to Protein Design Labs

9. Novel Trials with Canarypox Virus Vector HIV Vaccine

10. Bristol-Myers Squibb Drops License to Market Lidakol for HSV

11. SKB Links with MedImmune for HPV Vaccines

12. SKB Links with Virus Research Institute for Rotavirus Vaccine Development

13. Thymosin Alpha 1 Enters Pivotal Phase III Hepatitis B Trial in Japan

14. Hoffmann-La Roche Links with Progenics for HIV Co-Receptor Drug Development

15. Topical Interferon Trials for Vaginal Genital Warts

16. Natural Interferon Enters Phase II Trial for Hepatitis C/HIV Co-Infection

17. DMP 266 Expanded Access for HIV-Infection Broadened

18. Hepatitis C Virus Helicase Structure Reported

19. MedImmune Files for Approval of RSV Monoclonal Antibody

20. VIMRxyn Development Halted for HIV, HCV, Blood Sterilization; Continues for Warts

21. Ebola Vaccine Shows Indications of Efficacy in Animals

22. Study Finds SV40 in Inactivated Polio Vaccine is Not Linked with Increased Cancer

23. Second-Generation CMV Antisense Drug Enters Trials

24. Nelfinavir Approved in the European Union

25. LeukoSite and Warner-Lambert Extend Chemokine HIV Drug Collaboration

26. Blood Products Inactivation R&D Grants Available

27. Endorex and Elan Link for Vaccines Development

28. Cantab Links with Kaketsuken for VZV Vaccine Development

29. Ranitidine Not Effective for HIV-Infection

30. Theratechnologies and Chiron Link for HIV Vpr-Based Gene Therapy Development

31. Pasteur Merieux Connaught Extends Vaccine Adjuvant Collaboration with Corixa

32. Stem Cell Ribozyme Gene Therapy Trial Shows Feasibility

33. Protein in Saliva Has Anti-HIV Activity

34. HIV Immunotherapeutic Vaccine Induces HIV Subtype Cross Reactive Responses

35. Cross-Clade HIV Cellular Immunity

36. DuPont Merck Links with Signal for HCV and HIV Drug Development

37. Warning of Hypersensitivity with Abacavir

38. DMP-450 HIV Protease Inhibitor Trials Restart

39. First Successful Treatment for PML/JC Virus

40. Generic KaposiÕs Sarcoma Drug Approved But CanÕt Be Marketed

41. National Clinicians Post-Exposure Prophylaxis Hotline (PEPline)

42. New Information Sources

43. New Meetings

44. Virus Research Inst. Licenses Therapore Vaccine Delivery Technology

45. Antisense CMV Drug Shows Efficacy in Phase III Trial

46. HIV Protease Inhibitor Combinations May Reverse AIDS Dementia

47. Pharmacia & Upjohn Developing New HIV Protease Inhibitor, PNU-140690

48. Peptimmune Developing HIV Immunotherapeutic Vaccine

49. GM-CSF Shows Indications of Efficacy for Treatment of HIV-Infection

50. Amprenavir and HIV Protease Inhibitor Double Combinations Show Promise

51. Nelfinavir, HIV Protease Inhibitor, Shows Efficacy After Two Years

52. Interferon Shows Efficacy in Phase III Trial for Treatment of HIV-Infection

53. Ritonavir Shows Clinical Efficacy for Treatment of Advanced HIV-Infection

54. Expanded Access Program for Abacavir, HIV Reverse Transcriptase Inhibitor

55. Lasting Immune Responses with Remune, HIV Immunotherapeutic Vaccine

56. Warner-Lambert Divests Its Influenza Vaccine and Vidarabine

57. Multivalent Vaccinia Vector Prophylactic HIV Vaccine Enters Trials

58. Aviron Reports Consistency with Production of Live Influenza Vaccine

59. Genelabs Expands Antiviral Drug Discovery; Contracts with Three Companies

60. HIV Strain E Vaccine Enters Trials in Thailand

61. Drug Transport Inhibitors Could Boost Oral Bioavailability of HIV Protease Inhibitors

62. HIV Vaccine from VaxGen Entering Phase I and II Trials

63. Another Bomb Found at BioChem Pharma

64. Nevirapine, HIV NNRTI, Approved in Europe

65. HIV Protease Inhibitor, Nelfinavir, Approved in Japan

66. (+)-Calanolide A Meets Phase IA Trial Endpoints

67. ArQule and Sepracor Link for HIV and Hepatitis B Drug Discovery

68. Chiron and Pharmacia & Upjohn Link for Hepatitis C Drug R&D

69. Interleukin-1b Adjuvant/Novasomes Boost Vaccine Immune Response

70. Oral PMPA Prodrug Shows Promise for HIV-Infection

71. Vaccines and Drugs for the Hong Kong/Bird Flu

72. Reports from the Recent Retroviral Conference

73. Indinavir Granted Full FDA Approval

74. Saquinavir Soft Gel Joins Other Drugs as a ÒPreferredÓ HIV Protease Inhibitor

75. New Web Sites and Publications

76. Triangle Licenses L-FMAU from Bukwang Pharmaceuticals

77. Glaxo Wellcome Options HIV NNRTIs from Hoechst/Bayer

78. Foscarnet-Related Prodrugs Available for Licensing

79. Apollon Licenses Hepatitis B Antigens from Biogen

80. Chiron Charges Roche with Infringement of Hepatitis C Virus Patents

81. SciClone Gains Worldwide Rights to Thymosin alpha 1

82. Endorex Options Antigens for Use in Oral Hepatitis B Vaccines

83. Short Course of AZT Reduces Maternal Transmission of HIV

84. Prices Reduced for AZT Use in Pregnant Women in Developing Countries

85. Phase III Trials Insufficient to Approve Interferon for HIV and Hepatitis C

86. Additional Antisense CMV Drug Phase III Trial Results

87. Glaxo Wellcome Links with PowderJect for Hepatitis B and Other DNA Vaccines

88. Human Chorionic Gonadotropin Fractions Active Against HIV and KaposiÕs Sarcoma

89. Lodenosine (F-ddA) in Development for HIV-Infection

90. Adefovir Shows Indications of Efficacy for Treatment of HIV-Infection

91. Adefovir Shows Indications of Efficacy for Hepatitis B

92. Gene Therapy-Modified T-Cells Survive in HIV-Infected Patients

93. First Filing for Approval of Zanamivir for Treatment of Influenza

94. Tripos and Sepracor Link for HIV Drug Discovery

95. BioChem Pharma Bombings Linked to Stock Manipulation?

96. Ampligen Enters Phase III Trial for Chronic Fatigue Syndrome

97. Shionogi Conducting U.S. Trials with HIV NNRTI

98. Salmonella Vector HIV Vaccine Enters Trials

99. Common Cold Caused by Multiple Viruses

100. Nabi Links with CDC for Hepatitis C Virus Immune Globulin Testing

101. BioChem Pharma Links with Scriptgen for Hepatitis B Drug Discovery

102. First Approval of Low-Dose Oral Interferon for Hepatitis B

103. Immune Reconstitution Trial with Remune HIV Vaccine, IL-2 and Anti-HIV Drugs

104. Link Between HHV-8/KSHV and KaposiÕs Sarcoma Reported as Confirmed

105. Cidofovir is First Drug Reported Active Against Monkeypox

106. Chiron Completes Acquisition of European Vaccine Company

107. Histamine Increases Response to Interferon

108. Pfizer Drops HIV Ribozyme Collaboration with Immusol

109. Southern Health Options Leukocyte Interferon from Viragen

110. Hepatitis C Virus Vaccine in Clinical Trials

111. Combivir (AZT Plus Lamivudine) Approved in the European Union

112. Study Reports Acyclovir Does Not Improve AIDS Survival

113. Measles Vaccination Halting Disease in the U.S.

114. Pall Links with V.I. Technologies for Viral Inactivation Development

115. SKB Reports Sales of Hepatitis B Vaccine and Famciclovir

116. Drs. Purcell and Gerin Honored for Hepatitis Research

117. American Red Cross to Market Virus Inactivated Plasma

118. U.S. Patents Added to Antiviral Agents Bulletin Web Database

119. American Society for Microbiology Journals Going Online

120. New Publications

121. New Meetings

122. Intron A Use with Ribavirin Approved for Chronic Hepatitis C in Relapsed Patients

123. DISC Herpes Simplex Virus Vaccine Shows Safety and Immunogenicity

124. More Trials Show Lamivudine Effective for Hepatitis B

125. HIV Vaccines in Prime-Boost Regimen Induce Immune Responses

126. More Results from Nasal Spray Influenza Vaccine Phase III Trials

127. Famciclovir Can Prevent Laser Surgery-Related Orofacial Herpes

128. Phase III Hepatitis B Trial Starts; Other News with Thymosin Alpha 1

129. PEN203 in Trials for Topical Treatment of HPV Warts

130. CD7 Antibody-Pokeweed Antiviral Protein Immunotoxin in Trials for HIV-Infection

131. HIV Shown Able to Infect Activated CD8+ T-Cells; May Explain HIV Pathogenesis

132. American Home Products Corp. Acquires Apollon and DNA Vaccines

133. HIV DNA Vaccines Can Induce Specific Cytotoxic Responses

134. Intron A Plus Ribavirin Effective for First-Line Treatment of Chronic Hepatitis C

135. Reticulose Enters Phase III Trials for Genital Warts in HIV Patients

136. HIV Gene Therapy Vaccine Trial Abandoned in Japan

137. 3TC/Lamivudine Sales Approach One Billion Dollars Annually

138. Virco Links with LabCorp to Market HIV Drug Resistance Tests

139. Virus Research Institute Acquired by T Cell Sciences

140. Nabi to File for Approval of New Hepatitis B Immune Globulin Formulation

141. Trial Shows Feasibility of Transgenic Foods for Vaccine Delivery

142. Aquila Acquires VacTex and Lipid Antigen Vaccine Technology

143. Pantheon to Manufacture Interferon Lozenges

144. T-20 HIV Trial Adds DMP 266/Sustiva

145. Rapid Influenza Diagnostics

146. Vaccine Company Formed in India; Rabies Vaccine is Initial Target

147. Schering-Plough Extends Hepatitis C Drug Collaboration with Corvas

148. Affymetrix and Roche Link for HIV Resistance PCR GeneChip

149. New Tonsil Tissue Model for HIV-Infection

150. Intranasal Influenza Vaccine Enters Trials

151. Solvent Detergent Inactivated Plasma Approved by FDA

152. New Director of NIH Office of AIDS Research

153. New Publications

154. HIV/AIDS Resources Directory

155. Theratechnologies Links with Genetix for HIV Vpr Gene Therapy Technology

156. Cantab Options Liposome Technology for Its Cervical Dysplasia Vaccine

157. First Large-Scale, Phase III Trials with a Prophylactic HIV Vaccine

158. Immune Response and Agouron Link to Develop HIV Immunotherapeutic Vaccine

159. Low Adherence to Treatment Regimens is Common Among HIV-Infected Patients

160. Passive Immune Therapy Reported Effective for Advanced HIV-Infection/AIDS

161. Human Hepatitis B Virus Antibody Plus Lamivudine Trials for Chronic Hepatitis B

162. HIV Drugs Reported to Cross Blood-Brain Barrier

163. Bursal Disease Virus Vaccine Shows Indications of Efficacy for Acute Hepatitis B/C

164. New Nucleoside Analog, BCH-10652, Enters Trials for HIV-Infection

165. Merck Links with Isis for Hepatitis C Drug Discovery

166. Maxamine/Interferon Combination Feasible for Hepatitis C

167. SKB Links with BioChem Pharma for Influenza Vaccines

168. American Home Products Acquires Monsanto

169. BTG Links with Swiss Serum and Vaccine Inst. for Hepatitis B Vaccine Commercialization

170. BMS Halts Development of Sorivudine, BV-araU

171. HIV gp120 Crystal Structure Reported

172. Reticulose Shows Indications of Efficacy for HIV-Infection

173. Dendritic Cell Therapy Reported of No Benefit for HIV

174. DuPont Buys Out MerckÕs Stake in Drug Company Joint Venture

175. Cytarabine Not Effective for PML in AIDS Patients

176. Hepatico Herbal Remedy to be Marketed for Hepatitis A, B and C

177. PRO 2000 Gel Prevents Vaginal Herpes in Mice

178. Ligand Seeks Approval of Panretin Gel for KaposiÕs Sarcom

179. Famciclovir Approved for Herpes Simplex Virus Infections in HIV Patients

180. New Publications and Web Sites

181. New Meetings

182. Nabi Licenses Novel Nucleosides/Nucleotides, Including Hepatitis B Drug

183. Lamivudine/3TC Patent Filings Declared in Interference

184. First Monoclonal Antibody Approved for an Infectious DiseaseÑRSV Infection

185. Gene Therapy Reduces HIV in Gastrointestinal Lymphoid Tissue

186. Chemokines Protect Hemophiliacs from HIV-Infection

187. Many U.S. Patients Receiving Suboptimal HIV Drug Treatment

188. Immune System Can Control HIV-Infection, If Treated Early Enough

189. HIV in T-Cells Rebounds After Halting Therapy; ÒPurgingÓ Regimen Suggested

190. Yellow Fever Virus Vector Flavivirus Vaccines in Development

191. HIV Can Be Resistant to All Available Drugs; Resistant HIV is Transmissible

192. Amprenavir, HIV Protease Inhibitor, May Contribute to Immune Reconstitution

193. GS 4104 Shows Efficacy for Influenza in Phase II/III Trials

194. Nuclear Importation Inhibitors and Cyclophilin A Antibody for HIV-Infection

195. Trial Shows Adefovir Not Associated with HIV Resistance

196. May 1998 U.S. Prescriptions for Anti-HIV Drugs

197. Aviron Links with CSL for Commercialization of Intranasal Influenza Vaccine

198. Progenics and Pharmacopeia Link for HIV Drug Discovery

199. Nutritional Supplement Affects Apoptosis and Increases CD4+ T-Cell Count in HIV-Infection

200. Herpesvirus Receptor Reported

201. Meditech to Market Topical MTCH-24 for Oral Herpes

202. Hepatitis C Epidemic

203. Filing for Approval of Abacavir for HIV-Infection

204. Scherer to Make Soft Gel Fortovase

205. HIV-Infected Persons in U.S. Now Legally Disabled

206. FDA Approves First Urine Test for HIV Antibodies

207. New HIV-1 Diagnostic Approved

208. HIV PromptChart--Online HIV Patient Management

209. New Meetings

210. Agouron Licenses an HIV NNRTI and an HIV Protease Inhibitor

211. Alpha Interferon Patent Dispute Settled

212. ZymeTx Licenses HIV Drug

213. Chiron Files Suit in Japan Over Hepatitis C PCR Assays

214. Enzo Biochem Antisense Patent Reinstated

215. Nevirapine, HIV NNRTI, Approved for Use with Protease Inhibitors

216. Dual HIV Protease Inhibitor Combinations for First-Line Treatment

217. Intranasal Live Influenza Vaccine Shows Second Year of Efficacy in Children

218. Triangle Updates HIV and Hepatitis B Drug Development Activities

219. GM-CSF Shows Promise for Treatment of Advanced HIV-Infection/AIDS

220. Schering-Plough and Immune Response Link for Interferon Hepatitis Gene Therapy

221. Interferon Sciences Links with Genzyme Transgenics for Transgenic Interferon

222. Hydroxyurea, DDI and D4T Combination Shows Promise for HIV-Infection

223. Rabies DNA Vaccine 100% Effective in Monkeys

224. Acyclovir Suppresses Recurrence of Ocular Herpes

225. Efavirenz, HIV NNRTI, Combinations for First-Line Therapy

226. International Gaps Persist in the Treatment of HIV-Infection

227. Simultaneous Drug Combinations Better Than Sequential HIV Drugs

228. New Phase III and Other Trials with DDI for HIV-Infection

229. Study Shows D4T/DDI Better Than AZT/3TC

230. Lamivudine/3TC Sales Reported

231. New Transfusion-Transmitted Virus Does Not Appear to be Pathogenic

232. IL-2 Improves Immune Recovery in Advanced HIV/AIDS Patients

233. Estimated Global Cost of Triple Combination Therapy for HIV-Infection

234. Ribavirin Cream Approved in Russia for Herpes Indications

235. Schering-Plough Acquires European Rights to Ribavirin for Hepatitis C

236. PNU-140690, an HIV Protease Inhibitor, Shows Potential

237. HIV-Infected Women May Need to Start Treatment Earlier Than Men

238. Fortovase Effective When Used Twice Daily

239. D-D4FC Active Against HIV

240. More Sensitive HIV bDNA Assay Available

241. HGP-30W HIV Vaccine Enters Phase II Trials

242. Abbott has Problems with Ritonavir Manufacture; Substitutes Liquid Formulation

243. Glaxo Wellcome Files for Approval of Lamivudine for Hepatitis B; New Trial Results

244. Viragen Obtains Major U.S. Source of Leukocytes for Interferon Production

245. U.K. to Filter Out Leukocytes from All Blood and Blood Products

246. Pasteur Merieux Connaught Links with Cistron for IL-1b Vaccine Adjuvant

247. Glaxo Wellcome/Warner-Lambert OTC Joint Venture Dissolved

248. Boston Biomedica Awarded Contract for HIV Vaccine Trials Support

249. Dr. M. Johnston Assumes HIV Vaccine Posts at NIAID

250. New Publications

251. New Meetings

252. Chiron Charges Companies with Infringement Related to HCV Drug Discovery

253. First Antisense Oligonucleotide Drug ApprovedÑFomivirsen for CMV Retinitis

254. First Rotavirus Vaccine Approved

255. Live-Attenuated SIV Causes Disease; A Setback for Live HIV Vaccines

256. Aviron Must Resubmit FDA Application for Its Intranasal Influenza Vaccine

257. Hepatitis C Virus Antibodies and Immunotherapeutic Vaccine Active in Monkeys

258. Zanamivir Phase III Trial Shows Efficacy for Treatment of Influenza

259. First Approval of Lamivudine for Hepatitis B

260. HIV Multideterminant Cluster Peptide Vaccine in Clinical Trials

261. Phase III Trial Testing Valacyclovir for Reduction of Genital Herpes Transmission

262. C-Sections Reduce Risk of Maternal HIV Transmission

263. Phosphazide in Trials for HIV-Infection

264. Adefovir Shows Anti-HIV Activity Over 48 Weeks

265. Spermicide/Anti-HIV Agents Reported

266. T-Cell Homeostasis Collapse Precedes AIDS

267. Influenza Virus Virulence Factor Reported

268. RiboGene Links with EnzyMed for Drug Discovery

269. Schering-Plough Files for Rebetron First-Line Treatment of Hepatitis C

270. Intranasal Influenza Vaccine Not Sufficiently Immunogenic

271. Nelfinavir Approved in Canada

272. AMD3100 from AnorMED in Trials for HIV-Infection

273. Abbott Files for European Approval of RSV Monoclonal Antibody

274. Avipox Virus Vector HIV/Interferon-gamma Vaccine to Enter Trials

275. Intron A Approved for Pediatric Use in Chronic Hepatitis B

276. Hepatitis B Vaccine Approved for Patients with Chronic Hepatitis C

277. Influenza Vaccine from King Pharmaceuticals Approved

278. NIAID to Collaborate with VaxGen for HIV Vaccine Trials

279. NIAID Funds 12 Centers for AIDS Research

280. Second Facility Approved for Manufacture of RSV Monoclonal Antibody

281. Aviron Receives Grant for CMV Vaccine

282. New Meetings

283. CpG ImmunoPharmaceuticals Licenses S-Oligo Immune Stimulants

284. Lamivudine/3TC Patent Infringement Suit Stayed

285. Tanox Licenses Antibody Humanization Patents

286. SKB and Chiron Settle Expression Promoters Patent Dispute

287. Efavirenz, HIV NNRTI, Approved by FDA; Activists Protest Cost

288. Phase III Trial Results with HIV Protease Inhibitor Amprenavir; NDA Filed with FDA

289. More Results from Lidakol Phase III Trial for Oral Herpes

290. Phase III Trials Show GS 4104 Effective for Influenza Treatment

291. Inosine Monophosphate Dehydrogenase Inhibitor in Phase II Trials for Hepatitis C

292. HCV Activists Protest Cost of Ribavirin Bundled with Interferon

293. HE2000, a Cellular Energy Regulator, Enters Trials for HIV-Infection

294. MDI-P in Development for HIV Treatment

295. Rotavirus Vaccine from AVANT Shows Efficacy in Phase II Trial

296. Merck Halts Study of Twice-Daily Indinavir Plus HIV RT Inhibitors

297. J&J Links with BioCryst for Oral Influenza Drugs

298. Indinavir, HIV Protease Inhibitor, Shown Comparably Effective in Men and Women

299. HPV Vaccine Safe and Induces Antibodies

300. Market Shares of HIV Drug Regimens in the U.S.

301. Chiron Sells Diagnostics Subsidiary to Bayer

302. Low-Dose Oral Interferon Shows Indications of Efficacy for Measles

303. Abacavir/Combivir Shows Indications of Efficacy in Previously Treated Patients

304. Valacyclovir Reduces Asymptomatic HSV-2 Shedding

305. Amprenavir and Abacavir Show Strong Anti-HIV Synergy

306. Managed Care Costs for HIV Stabilized in 1997

307. AG7088, a Candidate Rhinovirus 3C Protease Inhibitor

308. Influenza Vaccination Rate Up in U.S.

309. Ring Expanded Nucleosides Active Against Hepatitis B Virus

310. Viragen Gains Access to Nearly All of the U.S. Leukocyte Supply for Interferon Production

311. Oral PMPA Prodrug Enters Phase II Testing

312. Multi-Faceted Expanded Access Program for Amprenavir

313. RSV Monoclonal Antibody Shows Promise for Stem Cell Transplants

314. Leukine (GM-CSF) HIV Vaccine Adjuvant Trial; Correction

315. FDA Approves Pediatric Formulation of Nevirapine

316. New Agencies Take Over Canadian Blood Supply

317. New Books and Databases

318. New Meetings

319. SKB Expands Licensing of Hepatitis E Virus Vaccine

320. MedImmune Licenses MF59 Adjuvant for Parvovirus Vaccine

321. Protein Design Labs and Genentech Cross-License Patents

322. Pasteur Merieux Connaught Licenses Vaccine Carrier Technology

323. Switch to Less Aggressive Therapy Does Not Maintain HIV Suppression

324. IL-2 Plus Antiretroviral Drugs Reduces Reservoir of HIV in Resting CD4+ T-Cells

325. Adefovir Shows Indications of Efficacy for Hepatitis B

326. Thymosin Alpha 1 Plus Nucleoside Analogs Shows Promise for Hepatitis B

327. Controlled-Release Acyclovir Phase II Trial Shows Efficacy for Genital Herpes

328. Dynamics of Hepatitis C Virus Infection Resemble that of HIV

329. Pleconaril Trial for Viral Meningitis Fails to Meet Primary Endpoint

330. HIV Immunotherapeutic Vaccine Plus Antiretroviral Drugs Shows Promise

331. First-Line Interferon-alfa Plus Ribavirin Effective in Phase III Trials for Hepatitis C

332. Aphios Developing Viral Inactivation, HIV Vaccines, Screening Marine Organisms

333. HIV-Infection Progression Different in Injection Drug-Using Women vs. Men

334. Glaxo Wellcome Files for European Approval of Amprenavir

335. Famciclovir Shows Efficacy for Genital Herpes Prevention in HIV-Infected Patients

336. Pasteur Merieux Connaught Links with Cistron for IL-1b Vaccine Adjuvant Technology

337. Phase III Trial Starts with WF10 for HIV-Infection

338. Agouron Raises Price of Nelfinavir, the Most Popular HIV Protease Inhibitor

339. Managed Care Costs Lower for HIV Patients with Undetectable Viral Loads

340. Medeva Files for European Approval of Hepatitis B Virus Vaccine

341. American Home Products and Monsanto Merger Canceled

342. OraVax to Merge with Peptide Therapeutics Group

343. FTC Shows Promise for Hepatitis B

344. Agritek Bio Acquires Veterinary Rights for Low-Dose Oral Interferon

345. Glaxo Wellcome Files NDA for Approval of Zanamivir for Influenza

346. RiboTargets Links with Molecular Simulations for RNA-Binding Drug Discovery

347. LifeTECH Abandons Ozone Blood Sterilization R&D

348. Hepatitis B Immune Globulin Plus Lamivudine Shows Promise for Liver Transplants

349. Intron A and Rebetron Combination Therapy Sales Increase

350. Agouron Links with BioStar for Rhinovirus Diagnostic Development

351. New Ampligen Formulation

352. CONDEA to Manufacture Lidakol Active Ingredient

353. Lamivudine on Track for FDA Approval for Hepatitis B

354. PRO 2000 Intravaginal Microbicide Enters NIAID-Supported Trial

355. New Publications

356. New Meetings

357. Tranzyme Licenses Lentiviral Vectors for HIV Drug Sensitivity Testing

358. FDA Approves the First Oral Treatment for Hepatitis B

359. Interferon Plus Ribavirin Approved for First-Line Treatment of Hepatitis C

360. Abacavir Approved for Treatment of HIV-Infection

361. Hepatitis B Immunotherapeutic Vaccine Shows Promise

362. South Africa Halts Funding of AZT for Pregnant Women

363. MPL Adjuvant Improves Response to Hepatitis B Vaccine in Low Responders

364. PMC and OraVax Link for Dengue Vaccine; Japanese Encephalitis Vaccine Optioned

365. Rhone-Poulenc and Hoechst Merging to Form Aventis

366. Inter-Company Collaboration Starts New Trial with HIV Drug Combinations

367. PEG-Interferon Trial Shows Promise for Hepatitis C; Patent Dispute Starts

368. SKB and BioChem Pharma Link for Influenza Vaccines; Trial Shows Promise

369. Large IAVI Grants for HIV Vaccines; Patent and Price Concessions Included

370. 3M and Vanguard Link to Develop Imiquimod Analog for Hepatitis C

371. HIV Zinc Finger Inhibitor, CI-1012, Development Halted

372. Pediatricians Issue New Polio Vaccine Recommendations

373. Viragen Signs $20 Million Natural Interferon Export Deal

374. Intranasal Rhinovirus 3C Protease Inhibitor Enters Trials

375. V.I. Technologies Receives $50 Million Order for Inactivated Plasma

376. Astra and Zeneca to Merge

377. AIDS Drug Assistance Programs (ADAPs) Quickly Adopt Efavirenz

378. CMV Immune Globulin Approved for Broader Indications

379. First Rapid Influenza Diagnostic Approved

380. New Publications and Databases

381. FDA Issues Letter Regarding Certain Viral Vaccines

382. Isis Pharmaceuticals Acquires Antisense Technologies from Gilead Sciences